A Study of BPI-460372 in Advanced Solid Tumor Patients
This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in solid tumor patients.
Advanced Solid Tumor
DRUG: BPI-460372
The adverse events (AEs), Safety and tolerability will be assessed by monitoring frequency, duration and severity of adverse events (AEs)., Through the Phase I, approximately 24 months|The dose-limiting toxicity（DLT）, The dose-limiting toxicity, Through the Phase I, approximately 24 months|Determine the Maximum Tolerated Dose (MTD), The MTD will be based on DLT., Through the Phase I, approximately 24 months
Evaluate the pharmacokinetics of BPI-460372, Based on blood plasma concentration, Time Frame: Through the Phase I, approximately 24 months|Evaluate the effectiveness of BPI-460372, Efficacy assessments (tumor evaluation) will be performed per RECIST1.1 or mRECIST1.1, Time Frame: Through the Phase I, approximately 24 months
This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in solid tumor patients.